1. Introduction
Non-communicable diseases (NCD) are the leading cause of disability and mortality globally, being responsible for 39.5 million deaths in 2015 [
1]. Diabetes mellitus (DM) is one of the four major NCDs, together with cardiovascular diseases, cancer, and chronic respiratory diseases [
2]. Diabetes prevalence is rising, representing a growing challenge to public health. A total of 415 million people were estimated to be diagnosed with diabetes worldwide in 2015, and it is expected that this number will rise to 642 million by 2040 [
3]. One study demonstrated worldwide prevalence trends increasing from 4.3 to 9.0% in men, and from 5.0 to 7.9% in women from 1980 to 2014, with steeper increase in low and middle-income countries [
4]. Brazil ranks fourth in the world in number of individuals with diabetes [
4]. The 2013 Brazilian National Health Survey (NHS) demonstrated self-reported prevalence of diabetes of 6.2% in the population aged 18 years or older, reaching 19.9% in those aged 65–74 years [
5]. This prevalence is certainly underestimated given other previous Brazilian studies with laboratory confirmation, which have shown that approximately half of individuals with diabetes were unaware of the diagnosis [
6,
7].
Studies have demonstrated that people with diabetes are at higher risk of hospitalization [
8,
9,
10,
11] and readmission than people without diabetes [
12,
13]. The diabetes economic burden is significant and is expected to increase over time. Global health expenditures related to diabetes and its complications were estimated at
$673 billion in 2015 [
3]. Such costs represent a significant portion of national health expenditures, varying from 2.5 to 15% by country, depending on availability and access to healthcare services [
14].
In the early 2000s, Brazil initiated a series of strategies aiming at increasing access of the population with diabetes and hypertension to healthcare services [
15] and providing early diagnosis for diabetes through a national population-based screening program [
16,
17]. Later, a National Strategic Plan for chronic NCD was developed and implemented [
18]. This plan, in accordance to the World Bank and the International Diabetes Federation, recommends countries conduct national studies of cost of illness and economic burden of diabetes [
3].
Healthcare in Brazil is provided by both public and private sectors. Public healthcare services are provided by the National Unified Health System (SUS), which offers, free of charge, universal health access covering about 75% of the population in the country [
19].
Demographic, epidemiological and nutritional transition processes, urbanization and economic and social growth contribute to the greater risk of developing chronic NCD. Diabetes, stroke, myocardial infarction, hypertension, cancer and chronic respiratory diseases account for about 80% of deaths in Brazil, reaching heavily poor sections of the population and more vulnerable groups, such as the population with low schooling and income [
18].
The full economic burden of diabetes in Brazil is still unknown. Hospitalization costs associated with diabetes and its complications are reported to be the most significant portion of direct medical costs. In this study, we estimated the number of hospitalizations due to DM and its complications and their economic burden in Brazil.
3. Results
We considered the national prevalence of undiagnosed diabetes as 12.4%, varying by age group and state (
Supplementary Table S2). As such, we estimated that 17,320,339 adult individuals in the country would have diabetes.
A total of 11.3 million hospitalizations were registered in 2014 in the SIH/SUS, of which 8,629,004 million (76.2%) were adults (20 or more years). Of these adult hospitalizations, 284,675 received an authorization for prolonged stay (AIH-5).
In 2014, an estimated 313,273 hospitalizations due to diabetes occurred in Brazil, corresponding to 3.6% of total hospitalizations and representing a hospitalization rate of 22.8/10,000 adults. Excluding hospitalizations for pregnancy, childbirth and the puerperium, hospitalizations attributable to diabetes represent 4.6% of total adult hospitalization in Brazil in 2014.
Among these, DM per se (ICD-10 codes E10–E14) accounted for 41.9% of hospitalizations, followed by cardiovascular diseases attributable to diabetes (26.5%) (
Table 1). The population hospitalization rates increased from 3.5 and 3.8/10,000 adults for men and women, respectively, aged 20–44 years to 146.0 and 133.3 for the age group of 75 and over. Women were hospitalized more than men when considering both absolute number and crude hospitalization rate. However, when considering age-standardized rates, these are higher for men (23.9/10,000 population) when compared to women (21.9/10,000 population). While the average cost of a hospitalization of an adult individual was Int
$709 in 2014, the average cost of a hospitalization due to diabetes and related diseases was 19% higher, reaching Int
$845. Among the hospitalizations due to diabetes, hospitalizations due to kidney (Int
$1602) and cardiovascular (Int
$1529) diseases were the ones with higher average cost, and hospitalizations due to diabetes had the lower average cost (Int
$364). Average hospitalization cost was significantly higher in men in all age groups and for all diagnosis groups, except for selected neoplasms, probably because of breast cancer costs included in this group (
Table 2).
Total costs for adult hospitalization in the SUS in 2014 were approximately Int
$6.1 billion. Admissions due to diabetes and related conditions reached Int
$264.9 million, representing 4.3% of total hospitalization costs. After excluding hospitalizations for pregnancy, childbirth and the puerperium, this proportion increased to 4.8%. Diabetes mellitus per se accounted for only 18.1% of total costs attributable to hospitalization due to diabetes and related conditions, with cardiovascular diseases attributable to diabetes (47.9%) accounting for the higher proportion of overall costs. Total hospitalization costs were significantly higher in men from 20–74 years. The reverse was observed in the age group of 75 years and older (
Table 3).
Among the hospitalizations with the main diagnosis reported as DM, the number of hospitalizations (52.5%), and total costs (46.2%) related to unspecified DM ICD-10 code E14) were the most observed, despite presenting the lower average hospitalization cost. The second most relevant cause of hospitalization in this group was insulin-dependent hospitalizations (ICD-10 E10), with the higher average hospitalization cost (
Table 4).
Cardiovascular diseases due to diabetes accounted for 13.1% (n = 82,958) of admissions and 14.3% (Int
$126,849,817) of costs of all hospitalizations for cardiovascular diseases in SUS. In hospitalizations due to diabetes, average hospitalization costs due to cardiovascular disease were 10.4% higher than non-diabetes hospitalizations. Among all hospitalizations due to cerebral infarction (ICD-10 code I63) and transient ischemic stroke and related syndromes (ICD-10 code G45), 25% of hospitalizations and costs could be attributed to diabetes (
Table 5).
Microvascular diseases due to diabetes (kidney, eye and neurologic diseases) accounted for a greater share of total hospitalizations (29.1%) and associated costs (24.5%). Of worth noting is the high number of hospitalization and overall costs with diabetes hospitalization due to renal diseases, in particular due to chronic kidney disease (ICD-10 code N18) (
Table 6).
Hospitalizations for respiratory and urinary infections, for which diabetes was considered a risk factor, represent a small percentage (5.3%) when compared to the cardiovascular (13.1%) and microvascular (29.1%) groups in relation to total SUS and accounted for 6.5% of hospitalizations due to DM. Even so, this percentage was reached due to the large participation of respiratory infections (96.5%) in this group, with emphasis on pneumonia per unspecified organism (ICD-10 J18) (69.9%) (
Table 7).
Hospitalizations for neoplastic diseases have a small participation (7.3%) of total hospitalizations in comparison with other groups and represent 2.7% of hospitalizations due to DM. Breast cancer (4.0%) and colorectal cancer (5.8%) admissions were among those with the lowest values, while cancers of endometrium (20.0%), pancreas (18.6%) and liver and intrahepatic bile ducts (22.6%) were among those with the highest values (
Table 8).
4. Discussion
Brazil is one of the most populated countries in the world, with an estimated population of 137.6 million adults in 2014 [
31]. Based on recent prevalence estimates, we have estimated that 17.3 million individuals aged 20 years and older had diabetes in Brazil (
Supplementary Table S2). Despite increasing trends in diabetes prevalence in the country, mortality due to diabetes declined 1.7% per year (from 40.6/100 thousand population to 33.7/100 thousand population) from 2000 to 2011, probably as a result of better access to healthcare, thus reducing mortality due to acute events [
32]. However, when diabetes was analyzed as an associated cause of death due to other causes, there was an increase of 8% between 2000 and 2007 [
33], most likely representing deaths due to chronic diabetes complications and related conditions.
Hospitalizations represent an important part of the consumption of health resources in different health systems and countries around the world and patients with type 2 diabetes had higher rates of hospitalization than the general population [
34]. In the United States in 2012, diabetes hospitalization costs were the most significant cost component (43%) of direct medical costs (
$176 billion) associated with diabetes, which added to
$245 billion when considering both direct and indirect costs [
25].
The estimated costs of hospitalizations due to diabetes and related conditions estimated in this study (Int
$264.9 million) represent 4.6% of all hospitalizations and 0.45% of all expenditures for actions and public services of health provided by the Ministry of Health in 2014 (Int
$58.3 billion) [
35]. In this same year, total health expenditures in Brazil were 8% of its Gross Domestic Product of which 46% was associated with public health expenditures (Int
$606 per capita) [
36]. This spending is equivalent to Int
$1.92 per adult by the federal government only with hospitalizations for DM and its complications. The average value of an adult hospitalization due to diabetes was 19% higher than a hospitalization without diabetes, and hospitalizations due to kidney and cardiovascular diseases were the ones with higher average cost.
Most countries in Latin America have adopted public health systems with universal coverage in the last few decades. Nonetheless, disparities in per capita government health expenditure can be observed in the region [
37] and a wide difference can be identified between countries that share historic similarities, with Venezuela with the lowest (Int
$270.88), and Cuba (Int
$2366.06) the highest per capita government health expenditure [
36]. When contrasting with high-income developed countries in other regions, disparities are more pronounced, with United States (Int
$4541.17), United Kingdom (Int
$2807.62), and Japan (Int
$3115.08) among the highest per capita expenditures [
36].
Our results demonstrated that the population aged 65 years and older used a much larger portion of hospital resources, both in number of hospitalization and costs, similar to results demonstrated in the United States in 2012 [
25]. Cardiovascular complications attributable to diabetes also represented the largest share of all hospitalizations, both in number of hospitalizations and costs.
Although when considering crude rates, women were more likely to be hospitalized than men, when adjusting for age taking into consideration the different age structure between men and women, men are more likely to be hospitalized than women. Although men had relatively higher hospitalization costs than women from age group 20–74 years, except for the ≥75 years age group, this may be due to the relatively longer life expectancy in women, compared with men [
38]. Hospitalizations reported as having diabetes as the main diagnosis were the most frequent (41.9%), although with lower costs. They currently represent a small proportion of all hospitalization expenses for the Brazilian National Health System, but are expected to increase considerably as the population ages. Moreover, hospitalization costs related to diabetes, but not captured by a first listed diabetes diagnosis, must be integrated with these costs to give a more comprehensive picture of the overall disease burden attributable to diabetes.
The total number of hospitalizations due to DM-related conditions was 2.4 times that of hospitalizations for first-listed DM; however, spending was almost 5.5 times higher. Microvascular diseases due to diabetes (kidney, eye and neurologic diseases) accounted for a greater share of total hospitalizations (29.1%) and associated costs (24.5%), part of which could be prevented with a better metabolic control. These results were in accordance with others that show hospitalizations for diabetes complications had a higher average cost than those for diabetes itself [
25,
39,
40].
The hospitalization costs due to infectious diseases and selected neoplasms in adults with DM were 4.8% and 3.9%, respectively, of the total hospitalizations due to DM. Although it represents a small percentage compared with vascular diseases, currently, this was the first Brazilian study to consider DM as an important contributor to such hospitalizations and costs.
Comparisons with Brazilian studies for 1999–2001 [
41] and 2008–2010 [
42], that used the same attributable risk methodology to estimate hospitalizations for DM in the Brazilian public network, should be performed with caution. In both previous studies, the results encompassed all age groups while in the current, only adults. In addition, in the two previous studies, hospitalizations were also estimated for the general medical conditions group, i.e., all other ICD-10 diseases that are not attributed to diabetes or its complications but for which individuals with DM were hospitalized more frequently. In contrast, in the current study, some of these conditions, such as certain neoplasms and lower respiratory and urinary tract infections, were computed as diabetes complications. It is also recognizable that the more recent literature has brought lower relative risks from international studies for the calculation of etiological fractions, although it was partially offset by the double of self-reported prevalence.
Our study has several limitations which are worth noting. The source of the data (SIH/SUS) was initially developed for administrative-financial functions for the purpose of collection and may not be free of coding errors, intentional or not. This is reflected by the high number of individuals hospitalized for whom the main diagnosis reported as DM was “unspecified DM—E14” (n = 68,987), and “insulin-dependent hospitalizations—E10” (n = 38,883), significantly higher than those reported as “non-insulin dependent diabetes—E11” (12,707). We believe that most of these cases reported as E14 are indeed individuals with type 2 DM. Also, many of the cases reported as E10 may be individuals with type 2 diabetes using insulin.
In addition, the SUS covers 75% of the population in Brazil, which means about one quarter of population with diabetes was not included in the data analysis, and thus our estimates may be underestimated. Moreover, the diabetes hospitalization rates may be different among those not covered by SUS. As SIH data do not incorporate critical variables with explanatory potential, such as body mass index, race, schooling, severity of the clinical condition at the time of hospitalization, degree of use of the services, readmissions and other, we are not able to identify the role of these possible factors in diabetes hospitalizations.
Another limitation is we considered only the adult population, as the focus of the study was on type 2 DM, which is more amenable to prevention strategies. As such, although hospitalizations due to type 1 DM may have been inadvertently included in our estimation, on the other hand, we might have underestimated cases of type 2 DM in those younger than 20 years of age.
Finally, as the more recent prevalence estimate available was that for self-reported diabetes [
5], to account for undiagnosed diabetes, and as done by other authors [
21], we applied a factor of 2, considering high quality recent evidence from Brazil [
7]. The resulting diabetes prevalence of 12.4% considered in our analyses is consistent with sub-national studies in Brazil which a decade ago showed 2 digit prevalence figures in selected regions of the country, being 12.1% in the city of Ribeirão Preto [
43], 12.4% in Porto Alegre [
44], and 13.5% in São Carlos [
45]. It is also consistent with prevalence estimates considered for global disease burden estimate studies [
21].